AstraZeneca stock price shows resilience above the $62 threshold despite pressure from sector-wide profit-taking. Fundamentals remain attractive for long-term growth, supported by diversified therapeutic pipelines. President Trump has announced that pharmaceutical tariffs, including those affecting AstraZeneca products, could take effect shortly. The tariffs are expected to roll out at lower initial rates and increase over time. A shift in AstraZeneca’s listing would be a big loss for the London Stock Exchange, which has already suffered a string of departures by companies seeking higher valuations. AstraZeneca stock price currently hovers around $63.40, showing a mild 0.8% uptick in early trading. Analysts note strong buying momentum in the healthcare sector, fueled by defensive positioning amid market volatility. Institutional interest remains high, supported by consistent revenue growth from oncology products.